Parenteral nutrition after cytoreductive surgery for peritoneal malignancy: Should it be administered routinely?

被引:1
作者
Khan, Ayman [1 ,3 ]
Beaumont, Anna [2 ]
Laing, Erin [2 ]
Guerra, Glen [1 ]
Jain, Anshini [1 ]
Warrier, Satish [1 ]
Heriot, Alexander [1 ]
机构
[1] Peter MacCallum Canc Ctr, Div Canc Surg, 305 Grattan St, Melbourne, Australia
[2] Peter MacCallum Canc Ctr, Victorian Comprehens Canc Ctr, Nutr & Speech Pathol Dept, Melbourne, Australia
[3] Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Australia
关键词
Cytoreductive surgery; Peritoneal malignancy; Perioperative nutrition; Parenteral nutrition; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; ERAS(R) SOCIETY RECOMMENDATIONS; GUIDELINE CLINICAL NUTRITION; ENHANCED RECOVERY; GASTROINTESTINAL SURGERY; PERIOPERATIVE CARE; ENTERAL NUTRITION; MANAGEMENT;
D O I
10.1016/j.clnesp.2023.06.016
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Purpose/background: Cytoreductive surgery (CRS) is complex abdominal surgery that is used to treat peritoneal malignancy. CRS is associated with major morbidity and efforts to address this include optimisation of perioperative care. There is variation in international protocols on the nutritional management after CRS, in particular whether parenteral nutrition (PN) should be routinely or selectively administered. Hypothesis/aim: This study assessed parenteral nutrition use, factors associated with PN requirement and nutritional outcomes in a centre that selectively uses PN after CRS. Methods/interventions: A retrospective analysis was undertaken on patients who underwent cytoreductive surgery +/- hyperthermic intraperitoneal chemotherapy (HIPEC) at Peter MacCallum Cancer Centre between 1st January 2015 and 31st December 2020 using data entered into a prospectively maintained database. Patient characteristics, nutritional status, oncological parameters, operative details and postoperative outcome data were retrieved. Categorical variables were compared using the chisquared test and continuous data was compared using a non-parametric ManneWhitney U-test. A pvalue <0.05 was considered statistically significant. Cox regression analysis was performed to identify independent predictors of requiring PN and postoperative weight change over admission. Results: A total of 222 patients who had CRS between were included (mean age 56 years; female 61.3%). Preoperative nutritional characteristics of participants included a mean body mass index (BMI) of 27.6 kg/m2 and the majority (77.9%) were not at nutritional risk pre-operatively with a Patient Generated Subjective Global Assessment (PG-SGA) score of category A. A high proportion of patients had surgery for colonic adenocarcinoma (58.1%), received HIPEC (87.4%) and achieved complete cytoreduction (82%). Postoperative parenteral nutrition was required for 65 patients (29.3%). The most frequent indication for PN was postoperative ileus (63.1%) with the mean (SD) time to commencing PN being postoperative day 5. Factors associated with the requirement for postoperative PN included preoperative albumin (OR 0.89; p = 0.015), weight loss >5% of body weight in the 6 months prior to admission (OR 2.2; p = 0.05), higher PCI score (OR 1.048; p = 0.005), number of anastomoses completed (OR 1.766; p = 0.017) and development of any postoperative complication (OR 2.71; p = 0.009). PN use was not associated with postoperative weight change. Conclusion: Most patients undergoing CRS did not require post-operative PN. Nutritional and operative factors may identify patients who are likely to need PN after surgery. Selective use of PN did not impact on postoperative weight change. (c) 2023 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:487 / 493
页数:7
相关论文
共 50 条
  • [21] Mortality and Morbidity after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
    Saxena, Akshat
    Morris, David L.
    VISZERALMEDIZIN, 2013, 29 (04): : 231 - 234
  • [22] Morbidity and mortality of patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Greta Hotza
    Michael Karageorgos
    Varvara Pastourmatzi
    Nader Baniowda
    Dimitrios Kyziridis
    Apostolos Kalakonas
    Nicolaos Chavouzis
    Irene Hotza
    Antonios-Apostolos Tentes
    Discover Oncology, 15
  • [23] Morbidity and mortality of patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Hotza, Greta
    Karageorgos, Michael
    Pastourmatzi, Varvara
    Baniowda, Nader
    Kyziridis, Dimitrios
    Kalakonas, Apostolos
    Chavouzis, Nicolaos
    Hotza, Irene
    Tentes, Antonios-Apostolos
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [24] Surgical Treatment of Patients With Peritoneal Surface Malignancy Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
    Dunn, Debra
    JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING, 2010, 37 (04) : 379 - 385
  • [25] The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing cytoreductive surgery: a retrospective study
    Altawil, Esraa
    Kalagi, Nora A.
    Alzahrani, Sohailah
    Alobeed, Faisal
    Alshammari, Sulaiman
    Bin Traiki, Thamer
    FRONTIERS IN NUTRITION, 2024, 11
  • [26] Microsatellite instability should not determine candidacy for cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in patients with peritoneal metastases from colorectal cancer
    Ruff, Samantha M.
    Hall, Lauren B.
    Choudry, M. Haroon
    Pingpank, James
    Holtzman, Matthew
    Bartlett, David L.
    Kim, Alex C.
    Ongchin, Melanie
    JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 28 (09) : 1493 - 1497
  • [27] Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer
    Bignell, M. B.
    Mehta, A. M.
    Alves, S.
    Chandrakumaran, K.
    Dayal, S. P.
    Mohamed, F.
    Cecil, T. D.
    Moran, B. J.
    COLORECTAL DISEASE, 2018, 20 (08) : 704 - 710
  • [28] Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre
    Keyes, Alan Martin
    Kelly, Michael Eamon
    McInerney, Niall
    Khan, Mohammad Faraz
    Bolger, Jarlath Christopher
    McCormack, Emilie
    Grundy, Josh
    McCormack, Orla
    MacHale, John
    Conneely, John
    Brennan, Donal
    Cahill, Ronan
    Shields, Conor
    Moran, Brendan
    Mulsow, Jurgen
    EJSO, 2021, 47 (09): : 2358 - 2362
  • [29] The cost of cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal malignancy in one Greek institute
    Tentes, A. A.
    Pallas, N.
    Korakianitis, O.
    Mavroudis, C.
    Spiridonidou, A.
    Zorbas, G.
    Popidis, S.
    Papadoniou, N.
    Darladima, V.
    Smyrnis, A.
    Siopis, C.
    JOURNAL OF BUON, 2012, 17 (04): : 776 - 780
  • [30] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Initial Report from Shiraz Surgical Oncology Group
    Akrami, Majid
    Khezri, Samad
    Tahmasebi, Sedigheh
    Karami, Mohammad Yasin
    Shiravani, Zahra
    Zangouri, Vahid
    Talei, Abdolrasoul
    Karimaghaei, Nazanin
    MIDDLE EAST JOURNAL OF CANCER, 2022, 13 (03) : 458 - 465